Zobrazeno 1 - 3
of 3
pro vyhledávání: '"I Toledo-Guasp"'
Autor:
MP Ortega-Garcia, I Toledo-Guasp, R Laguía-Sánchez, R Fuster-Talens, C Pedrós-Cholvi, A Bernalte-Sesé, P Blasco-Segura
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e34ec2f7b0b2e429cda732a3aad3ed46
https://doi.org/10.1136/ejhpharm-2022-eahp.200
https://doi.org/10.1136/ejhpharm-2022-eahp.200
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Adherence to treatment is a key factor in the control of symptoms of multiple sclerosis and the risk of relapses with adherence exceeding 80–85% is lower. Oral treatments can improve adherence. Aim and objectives To evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44a5d526964f5f0ebe46e428ff451f43
https://doi.org/10.1136/ejhpharm-2020-eahpconf.224
https://doi.org/10.1136/ejhpharm-2020-eahpconf.224
Autor:
R del Rio San Cristobal, A Lopez Carrasco, I Toledo Guasp, J Sanfeliu Garcia, P Blasco-Segura, V Merino Martin, MP Ortega-Garcia
Publikováno v:
Eur J Hosp Pharm
BACKGROUND: Monoclonal antibody PCSK9-Inhibitors (PCSK9i), alirocumab and evolocumab, are a new class of drugs used to decrease LDL cholesterol (LDLc) and can be an option for patients with heterozygous familial hypercholesterolaemia (HeFH) and cardi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01a45d6e49f3666fed81fc934db8dc62
https://europepmc.org/articles/PMC7535419/
https://europepmc.org/articles/PMC7535419/
